Structure Therapeutics (NASDAQ:GPCR) Given New $105.00 Price Target at JPMorgan Chase & Co.

Structure Therapeutics (NASDAQ:GPCR) had its price objective increased by JPMorgan Chase & Co. from $65.00 to $105.00 in a report issued on Thursday,Benzinga reports. The firm currently has an overweight rating on the stock.

Other research analysts have also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Wednesday, October 8th. HC Wainwright raised their price target on shares of Structure Therapeutics from $60.00 to $90.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Wall Street Zen upgraded shares of Structure Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Citigroup reiterated an “outperform” rating on shares of Structure Therapeutics in a research note on Friday, December 12th. Finally, Piper Sandler restated an “overweight” rating on shares of Structure Therapeutics in a research report on Tuesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.45.

Structure Therapeutics Trading Down 2.0%

NASDAQ:GPCR opened at $91.87 on Thursday. The company has a market capitalization of $5.57 billion, a P/E ratio of -75.30 and a beta of -2.05. Structure Therapeutics has a 12 month low of $13.22 and a 12 month high of $94.90. The firm has a fifty day simple moving average of $59.82 and a 200-day simple moving average of $36.02.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). Equities analysts forecast that Structure Therapeutics will post -0.82 EPS for the current year.

Institutional Trading of Structure Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. State of Wyoming acquired a new stake in Structure Therapeutics during the second quarter valued at $28,000. EverSource Wealth Advisors LLC grew its position in shares of Structure Therapeutics by 530.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after acquiring an additional 901 shares during the period. Assetmark Inc. grew its position in shares of Structure Therapeutics by 39.9% during the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after acquiring an additional 820 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Structure Therapeutics by 29.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after purchasing an additional 994 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd raised its holdings in Structure Therapeutics by 39.1% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after purchasing an additional 1,146 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.